National Mesothelioma Virtual Bank

2018-Annual Face to Face Meeting
(http://www.mesotissue.org)
Supported by CDC/NIOSH Grant U24OH009077

Waqas Amin, MD MS
Program Coordinator, NMVB
Senior Research Scientist
Department of Biomedical Informatics
University of Pittsburgh
Phone: 412-648-9069
waa8@pitt.edu
NMVB- Accomplishments:

- Continue to serve the translational research needs of the mesothelioma cancer research community.

- Collecting pleural and peritoneal malignant mesothelioma tissue samples (fresh frozen, fresh frozen paraffin embedded) and blood products from prospectively consented and retrospectively identified cases.

- NMVB is now providing five distinct tissue microarrays (TMA) for biomarker testing from each of the collaborating institutes.

- To date, 44 requests have been received and 42 request have fulfilled, representing 35 different Universities and Research Institutes. Thousands of biospecimens are shared to mesothelioma research community to facilitate novel biomarkers and therapeutic technique discoveries.
Expansion of NMVB resource to include new collections and sites:

- University of Maryland (UMD) has joined as a full collaboration partner in September 2016. UMD has a robust tumor banking infrastructure under the supervision of Drs. Joseph Friedberg, and Allen Burke.
- UMD has started to enroll prospectively consented patients since May 2017. UMD has enrolled 21 prospectively consented pleural and peritoneal mesothelioma cases and 91 retrospective peritoneal mesothelioma cases.
- UMD has developed 5th tissue microarray (TMA) and also contributed to fulfill the specimen request from mesothelioma research community.
- RPCI (Roswell Park Cancer Institute) has implemented prospective malignant mesothelioma specimen collection workflow and is providing fresh frozen and blood products since September 2016 for research.
NMVB database, for annotation and querying malignant mesothelioma biospecimens:

- NMVB database provides data entry interface to annotate biospecimen at demographics, clinical, pathology and follow-up (including staging, treatment and recurrence) dataset level.
- Public access statistical database for public query provides summary information on all the mesothelioma cases and their associated biospecimens stored into biorepository.
- Password protected database, provides user authentication level access and provides data entry interface to annotated biospecimens. (https://www.data.mesotissue.org/mvb/home.seam)
- Developing REDCap (Research Electronic Data Capture) instance to annotate and query mesothelioma specimens.
AVAILABILITY OF TUMOR TISSUE SPECIMEN (NMVB NETWORK OVERALL COLLECTION)

- Fresh Frozen (OCT), 616
- FFPE, 885
- Fresh Frozen (Bulk), 269
AVAILABILITY OF BLOOD PRODUCTS TYPE/# OF CASES (NMVB NETWORK OVERALL COLLECTION)

- Buffy Coat, 397
- Plasma, 581
- RBCs, 329
- Whole Blood, 352
- Serum, 556
**NMVB Collaborative Site Contribution:**

<table>
<thead>
<tr>
<th>Institutions</th>
<th>Retrospective Cases</th>
<th>Prospective Cases</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>NYU</td>
<td>185</td>
<td>129</td>
<td>314</td>
</tr>
<tr>
<td>U Penn</td>
<td>155</td>
<td>189</td>
<td>344</td>
</tr>
<tr>
<td>*MSSM</td>
<td>7</td>
<td>40</td>
<td>47</td>
</tr>
<tr>
<td>U Pitt</td>
<td>424</td>
<td>209</td>
<td>633</td>
</tr>
<tr>
<td>RPCI</td>
<td>76</td>
<td>0</td>
<td>76</td>
</tr>
<tr>
<td><strong>UMD</strong></td>
<td>91</td>
<td>21</td>
<td>112</td>
</tr>
<tr>
<td>Total</td>
<td>938</td>
<td>588</td>
<td>1526</td>
</tr>
</tbody>
</table>

*MSSM was joined NMVB from 2010 -2012. **UMD Joined in 2016
NMVB Tissue Microarrays (TMAs):

- Tissue Microarrays (TMA) are used to test simultaneous analysis of molecular targets at the DNA, mRNA, and protein levels under identical, standardized conditions on a single glass slide.

- Five distinct TMA are available – one from each NMVB site. In addition, we are planning to develop a collaborative TMA with contribution of specimens from all sites to address a broader range of research questions.

- These Five TMAs represents tumor tissue cores from 299 patients. Each tumor core annotated with tumor type, histological type, grade, stage and all clinical data.

NMVB Biospecimens Request Status Report:

SUMMARY OF SPECIMENS DISTRIBUTED
(2007-2018)

- Blood Products (# Aliquots), 1158
- Tissue Microarray Slides, 188
- Paraffin (Block), 815
- Fresh Frozen Section, 250

Average turnaround from initial request to getting specimens is about 6 - 8 weeks.
NMVB Marketing Efforts:

- NMVB Web site (www.mesotissue.org)
- NMVB Newsletter
- NMVB presence on social media, Facebook, LinkedIn, Twitter.
  - Facebook - @nmvb.org  https://www.facebook.com/nmvb.org
  - Twitter - @nmvbttw  https://twitter.com/nmvbttw
  - LinkedIn - @nmvb (https://www.linkedin.com/in/mesothelioma-virtual-bank-302b11131/)
- Presenting NMVB at national conferences (AMIA, USCAP, Meso-Foundation, iMiG, Heat and Frost Insulator Union).
http://www.mesotissue.org/

The National Mesothelioma Virtual Bank (NMVB) collects and distributes tumor tissue and blood samples to the research community from consented patients. The specimens are stored with de-identified clinical data and that is made available for research. Investigators can search the study database to identify and request these materials via the NMVB website. NMVB is the largest and most accessible resource for biospecimens donated by mesothelioma patients.

NMVB currently has 1380 annotated cases and 1702 biospecimens including Paraffin Embedded Tissue, Fresh Frozen Tissue and Blood

Services
Consultation and interpretive services are available: trained pathologists can provide assistance in staining, interpretation, scoring, and basic statistical analysis.

NMVB Database
 Allows researchers to search clinically annotated mesothelioma biospecimens and standardized clinical annotation structure to incorporate data from

Specimens (Availability)

- Fresh Frozen
NMVB Website-Audience:

All Web Site Data

Audience Overview

Overview

Users 1,072
New Users 1,063
Sessions 1,599
Pageviews 4,161
Pages / Session 2.60
Avg. Session Duration 00:02:20
Bounce Rate 50.97%

New Visitor 99.58%
Returning Visitor 0.42%

Language

<table>
<thead>
<tr>
<th>Language</th>
<th>Users</th>
<th>% Users</th>
</tr>
</thead>
<tbody>
<tr>
<td>en-us</td>
<td>782</td>
<td>72.88%</td>
</tr>
<tr>
<td>(not set)</td>
<td>90</td>
<td>8.39%</td>
</tr>
<tr>
<td>ko</td>
<td>68</td>
<td>6.34%</td>
</tr>
<tr>
<td>en-gb</td>
<td>29</td>
<td>2.70%</td>
</tr>
<tr>
<td>fr</td>
<td>24</td>
<td>2.24%</td>
</tr>
<tr>
<td>other</td>
<td>11</td>
<td>1.03%</td>
</tr>
</tbody>
</table>
Goals to Accomplish During 2018:

- Constructing the mesothelioma protein interactome, a project to discover/predict novel Protein-Protein Interactions (PPIs) of genes implicated in mesothelioma genes.

- Continue to enhance marketing efforts to publicize the resource to larger community of investigator to increase the utilization of resource.

- Continue to improve the consenting and collection workflow to increase the accrual of prospective mesothelioma cases.

- Developing collaborative Tissue Microarray slides.

- Replacing the existing specimen annotation and query application with REDCap instance.

- Continue to engage investigators who has obtained specimens from NMVB resource. To collect information about the publications and grant awards that are originated from the use NMVB resource via online feedback forms (https://www.mesotissue.org/node/88).
Acknowledgements

Collaborators:
- Center for Disease Control and Prevention (CDC)
- National Institute of Occupational Safety & Health (NIOSH)
- Mesothelioma Foundation (Meso Fndn)
- Mount Sinai School of Medicine (MSSM)
- New York University (NYU), New York City, NY
- University of Pennsylvania (U Penn), Philadelphia, PA
- University of Pittsburgh (U Pitt), Pittsburgh, PA
- Roswell Park Cancer Institutes (RPCI), Buffalo, NY
- University of Maryland, Baltimore, MD

Leadership:
- Michael J. Becich MD, PhD (U Pitt)
- Jonathan Silverstein MD, MS, FACS, FACMI (U Pitt)
- Harvey I. Pass MD (NYU)
- Douglas Hartman MD, PhD (U Pitt)
- James Luketich M.D (U Pitt)
- James Pingpank, MD (U Pitt)
- Carmelo Gaudioso (RPCI)
- Joseph Friedberg, MD (UMD)

- Michael Feldman MD (U Penn)
- Jonathan Melamed MD (NYU)
- Rajiv Dhir MD (U Pitt)
- David Bartlett, MD (U Pitt)
- Wiam Bashra, MD (RPCI)
- Mary Hesdorffer (Meso Fndn)
- H. Richard Alexander, MD (UMD)
- Allen Burke, MD (UMD)
Thank you